An engineered esophageal graft supported oral feeding, growth and contractile function in a study of eight minipigs. The result addresses a difficult problem in tissue engineering: replacing a full circular segment of the food pipe while preserving the muscle activity needed to move food toward the stomach.
The experiment was designed as a pediatric-scale model for long-gap esophageal atresia, a congenital condition in which the upper and lower parts of the esophagus do not connect. It was not a trial in children, and it did not test treatment for neurological swallowing disorders.
All eight animals survived the first 30 days, but only five reached the planned six-month endpoint. Complications were frequent and required repeated endoscopic management, making the study more informative—and less clinically complete—than a simple claim that lab-grown tissue “restored swallowing.”
How the 2.5-Centimeter Graft Was Made
The researchers began with donor pig esophagi and removed their cells, leaving the extracellular scaffold. They then collected small abdominal muscle and fascia biopsies from each recipient pig, expanded muscle progenitor cells and fibroblasts, and injected those cells throughout the scaffold.
The graft spent one week in a flow bioreactor. Cell collection, expansion, scaffold seeding and maturation took about eight weeks in total. Surgeons then replaced a 2.5-centimeter full-thickness section of the thoracic esophagus in each growing minipig.
The operation involved more than the graft alone. The team inserted a biodegradable stent to keep the passage open and wrapped the graft with pleural tissue to promote blood-vessel growth. Those supporting steps are part of the experimental strategy and cannot be separated from the functional outcome.
Five of Eight Animals Reached Six Months
All animals received water immediately after surgery and began a liquid diet the following day, moving gradually to more textured food. None required supplementary enteral feeding during the study, and their growth tracked the reference curve for healthy minipigs.
Five animals, or 63%, reached the planned six-month endpoint. The other three reached humane endpoints at one or three months after using the maximum number of endoscopic procedures allowed by the study license. The paper included all eight animals in its analysis.
At the later endpoints, tests found peristaltic pressure across the graft in five of seven animals assessed. Tissue analysis showed progressive development of epithelium, muscle, nerves and blood vessels. The five animals that reached six months were eating orally and were asymptomatic at that point.
Strictures and Polyps Required Treatment
Every animal developed symptomatic narrowing after a stent migrated or degraded. The strictures ranged from mild to severe and were treated with balloon dilation followed by replacement stents. The median number of dilations was 2.5, with a range from one to six.
All eight animals also developed hyperplastic epithelial polyps early after surgery. Seven received oral steroids and five underwent endoscopic removal. Some animals required additional procedures after swallowing bedding material, a complication specific to the model but still relevant to the intervention burden.
There were no anastomotic leaks, pneumothoraces or infections in the first 30 days. Four of the five six-month survivors needed no endoscopic intervention after month three, suggesting that narrowing became less severe over time. With only five animals at that endpoint, however, the result cannot establish a long-term complication rate.
This Is a Pediatric Animal Model, Not a Human Treatment
The experiment was a single-arm feasibility and safety pilot with no control group. Its primary outcome and main secondary outcomes could not be blinded. Eight animals are enough to demonstrate that the combined graft, stent, wrap and surgical approach can function in this model; they are not enough to estimate safety or effectiveness in children.
The work is most directly relevant to long-gap esophageal atresia. UCL says about 180 babies are born with esophageal atresia in the UK each year and roughly 10% have the long-gap form. Current operations may use the stomach or intestine to bridge the gap when the child's own esophagus cannot be joined.
Before a human research trial, the team plans more safety work, longer grafts, standardized manufacturing, better cell tracking and improved blood-flow support. A stated hope to begin a trial within five years is a research goal, not a timetable for routine care.
The study clears an important preclinical hurdle while exposing the next ones. A graft that contracts and supports feeding is more meaningful than tissue that merely survives. But a procedure that produced strictures in every animal and required repeated interventions is not ready to be described as a proven therapy for children.